ABS-1230
Phase 2Small molecule
ABS-1230 is one of 48 small molecule programs targeting Epilepsy. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Fycompa
CCatalyst Biosciences
Approved
Diamox
TevaApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Coreg
Akero TherapeuticsApproved
Glucophage
EMD SeronoApproved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABS-1230. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AActio Biosciences, Inc.